Day 1 | Day 2 | Day 3 | Download Brochure 

MONDAY, OCTOBER 20


PRE-CONFERENCE SHORT COURSES*

9:00am-12:00pm

(SC1) Imaging Technologies for Target Discovery 
Over the last few years it has become evident, that imaging technologies are a very useful tool in drug discovery. This course is designed to provide information on optical and molecular imaging tools and the challenges, opportunities and limits will be discussed. An overview on optical and molecular imaging will be  given.
Topics to be covered:

  • Overview and Introduction of current imaging technologies
  • Strength and limitations of using molecular imaging
  • Imaging with fluorescent proteins
  • Live animal imaging

Tutors:
Richard M. Levenson, M.D., Vice President, CRI
Cristian Badea, Ph.D., Assistant Professor of Radiology, Center for In Vivo Microscopy, Duke University Medical Center
Natalia E. Broude, Ph.D., Research Associate Professor, Department of Biomedical Engineering, Boston University

2:00-5:00pm
(SC6) Screening For Potential Drug Targets - Design Strategies for Novel-Generation Kinase Inhibitors
 
The structural coverage of the human kinome has significantly increased in the last few years. This course will provide useful insights and information on how fragment-based design offers an opportunity for assembling novel inhibitors, monitoring their binding kinetics and improving the residence time. Specific focus on screening technologies such as X-rays will be given.
Topics to be Covered:

  • Fragment-Based Inhibitor Assembly
  • Monitoring Binding Kinetics
  • Aiming at long residence time on target
  • Privileged Fragments with cross-target promiscuity within the kinase family fragments with front-loaded bindng kinetics characteristics

Tutors:
Tailor Made Biochemical Assays for Measuring Residence Time
Lars Neumann, Ph.D., Group Leader Assay Development & Screening, Proteros GmbH

X-ray Supported Fragment-Based Design
Gerhard Müller,Ph.D, Chief Scientific Officer, Proteros Fragments, GmbH

Doris Hafenbradl, Ph.D., Executive Vice President, Screening & Proteins, Proteros Biostructures

Frank Leemhuis, Ph.D., Managing Director, MercaChem

*separate registration required